Effect Of Calcitriol On Neutrophil To Lymphocytes Ratio And High Sensitivity C-Reactive Protein Covid-19 Patients

Universitas Sebelas Maret

Status and phase: Completed; Phase 2

Conditions: COVID-19

Treatments: Other: Placebo; Drug: Calcitriol

Study type: Interventional

Funder types: Other

Identifiers

NCT05765617

NAP03

Details and patient eligibility

About

This research is a study that compares the administration of calcitriol with the outcomes of COVID-19 patients

Full description

This research was an observational analytic cohort retrospective study in which the subjects were moderate degree COVID-19 inpatients in Sebelas Maret University Hospital divided into two groups. The control group received standard therapy, while the treatment group received calcitriol 2x400 iu per day.

Enrollment: 16 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• COVID-19 patients, hospitalized patients, and patients aged 18-60 years

Exclusion criteria

• pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

16 participants in 2 patient groups, including a placebo group

Control

Placebo Comparator group

Description:

Placebo 2x1 per day

Treatment:

Other: Placebo

Calcitriol

Experimental group

Description:

the treatment group received calcitriol 2x400 iu per day for 5 day

Treatment:

Drug: Calcitriol